19-norvitamin D analogs for breast cancer therapy1

Yotaro Matsumoto, Atsushi Kittaka, Tai C. Chen

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


The active form of vitamin D3, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3 or calcitriol), is known to inhibit the proliferation and invasiveness of many types of cancer cells, including breast, colon, pancreatic, prostate, and liver cancer cells. These findings support the use of 1α,25(OH)2D3 for the treatment of these types of cancer. However, 1α,25(OH)2D3 can cause hypercalcemia, so analogs of 1α,25(OH)2D3 that are less calcemic but exhibit more potent anti-tumor activity would be good candidates as therapeutic agents. Therefore, a series of 19-norvitamin D analogs, in which the methylidene group on C19 is replaced with 2 hydrogen atoms, have been synthesized by several laboratories. In our laboratory, we have designed and synthesized a series of 2α-functional group substituted 19-norvitamin D3 analogs and examined their anti-proliferative activity. Among them, 2α- and 2β-(3-hydroxypropyl)-1α,25-dihydroxy-19-norvitamin D3 (MART-10 and MART-11) were found to be the most promising. Here, we review the rationale and approaches for the synthesis of different 19-norvitamin D analogs, and the pre-clinical studies using these analogs in breast cancer cells, in particular, we chose MART-10 for its potential application to the prevention and treatment of breast cancer.

Original languageEnglish
Pages (from-to)333-348
Number of pages16
JournalCanadian Journal of Physiology and Pharmacology
Issue number5
Publication statusPublished - 2015 Mar 3
Externally publishedYes


  • 1α, 25-dihydroxyvitamin D
  • CYP24A1
  • MART-10
  • Synthesis
  • Vitamin D receptor

ASJC Scopus subject areas

  • Physiology
  • Pharmacology
  • Physiology (medical)


Dive into the research topics of '19-norvitamin D analogs for breast cancer therapy1'. Together they form a unique fingerprint.

Cite this